Prisys Biotech is a renowned contract research organization specializing in providing in vivo research solutions using Nonhuman Primates (NHPs) as disease models. Their mission is to provide the scientific community with reliable and high-quality research services to enable the development of novel therapeutics. Prisys Biotech is committed to upholding the highest standards of human clinical practice, ensuring the delivery of robust NHP pharmacology evidence to support the development of new therapeutics across the early discovery, non-clinical, preclinical, and early clinical stages.

Prisys Biotech's expertise lies in the areas of pharmacokinetics, pharmacodynamics, toxicology, safety pharmacology, and disease models using NHPs. The use of NHPs in research is essential due to their genetic and physiological similarities to humans, and their contributions have significantly impacted our understanding of diseases. Prisys Biotech recognizes the importance of NHPs in research and utilizes them extensively in their studies, breeding and maintaining a large colony under controlled conditions to ensure their health and welfare.

In vivo research is a crucial aspect of drug development, providing evidence for the safety and efficacy of new therapeutics. However, conducting such research using human subjects is often not feasible or ethical. Prisys Biotech's strong focus on technological innovation in the field of NHP pharmacology aims to advance research in this area and facilitate the translation of findings to human applications. As a leading player in the field of NHP pharmacology, Prisys Biotech is a valued partner to pharmaceutical and biotechnology companies worldwide.

NHP Chronic kidney disease (NHP-CKD) development and therapeutic effect of an anti-fibrotic compound, measured by serial biopsies

http://www.prisysbiotech.com/